Results for tag: "Chronic Inflammatory Demyelinating Polyradiculoneuropathy Drug"

Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) is a rare neurological disorder that affects the peripheral nervous system. It is an autoimmune disorder that causes inflammation of the myelin sheath, the protective covering of the nerves. CIDP is a long-term condition that can cause muscle weakness, numbness, and pain in the arms and legs. Treatment for CIDP includes immunomodulatory drugs, corticosteroids, and intravenous immunoglobulin (IVIG). The CIDP drug market is a subset of the Central Nervous System (CNS) drug market. CNS drugs are used to treat a variety of neurological disorders, including CIDP. The CIDP drug market is expected to grow due to the increasing prevalence of CIDP and the development of new treatments. Some companies in the CIDP drug market include Biogen, Merck, Novartis, Pfizer, and Sanofi. These companies are involved in the development and marketing of drugs for the treatment of CIDP. Show Less Read more